Skip to main content

Table 1 Difference of clinical characteristics between patients underwent MSD-HSCT and haploidentical HSCT (HID-HSCT

From: Long-term survivors demonstrate superior quality of life after haploidentical stem cell transplantation to matched sibling donor transplantation

Characteristics

All patients (n = 279)

P

One-year survivors (n = 230)

P

MSD-HSCT (N = 182)

HID-HSCT (N = 97)

MSD-HSCT (N = 153)

HID-HSCT (N = 77)

Age

37.87 (11.59)

33.07 (12.32)

0.00b

37.71 (11.438)

34.25 (11.703)

0.03b

Gender Male

90 (49.45)

51 (52.58)

0.71

77 (50.33)

38 (49.35)

1.00

 BMI ≥ 25

58 (31.87)

29 (29.90)

0.79

46 (30.07)

25 (32.47)

0.76

 Education (years)

  

0.42

  

0.67

  < 6

5 (2.75)

6 (6.19)

 

5 (3.27)

4 (5.19)

 

 6 ~ 12

124 (68.13)

60 (61.86)

 

102 (66.67)

48 (62.34)

 

  > 12

53 (29.12)

32 (32.99)

 

46 (30.07)

25 (32.47)

 

Marital status

  

0.02b

  

0.08

 Single

39 (21.43)

35 (36.08)

 

31 (20.26)

26 (33.77)

 

 Married

141 (77.47)

60 (61.86)

 

120 (78.43)

50 (64.94)

 

 Divorced/widowed

2 (1.10)

2 (2.06)

 

2 (1.31)

1 (1.29)

 

Main caregivers

  

0.02b

  

0.03b

 Spouse

74 (40.66)

53 (54.64)

 

59 (38.56)

42 (54.55)

 

 Alternative

109 (59.89)

44 (45.36)

 

94 (61.44)

35 (45.45)

 

Family income (rmb/year)

  

0.15

  

0.08

  < 100000

81 (44.51)

33 (34.02)

 

69 (45.10)

24 (31.17)

 

  ≥ 100000

94 (51.65)

57 (58.76)

 

79 (51.63)

48 (62.34)

 

Source of medical payment

  

0.36

  

0.89

 Insurance

111 (60.99)

64 (65.98)

 

96 (62.75)

49 (63.63)

 

 Self-payment

70 (38.46)

31 (31.96)

 

56 (36.60)

27 (35.06)

 

Diagnosis

  

0.01b

  

0.09

 AML/ALL

117 (64.29)

79 (81.44)

 

98 (64.05)

61 (79.22)

 

 MDS/MPN

48 (26.37)

16 (16.49)

 

42 (27.45)

14 (18.18)

 

 AA

15 (8.24)

2 (1.10)

 

11 (7.19)

2 (2.60)

 

 Lymphoma

2 (1.10)

0

 

2 (1.31)

0

 

Cytogenetic Data

  

0.57

  

0.29

 Normal

121 (66.48)

68 (70.10)

 

102 (66.67)

58 (75.32)

 

 Monosomal karyotype

32 (17.58)

11 (11.34)

 

29 (18.95)

7 (9.09)

 

 Complex karyotype

18 (9.89)

12 (12.37)

 

14 (9.15)

8 (10.39)

 

 Unable to define the karyotype

11 (6.04)

6 (6.19)

 

8 (5.23)

4 (5.19)

 

Hematologic Response at HSCT

  

1.00

  

0.88

 CR

130 (71.43)

69 (71.13)

 

110 (71.90)

54 (70.13)

 

 Non-CR or untreated

52 (28.57)

28 (28.87)

 

43 (28.10)

23 (29.87)

 

ECOG Performance Score

  

0.89

  

0.31

 0 (fully active)

121 (66.48)

66 (68.04)

 

95 (62.09)

54 (70.13)

 

  > 0

61 (33.52)

31 (31.96)

 

58 (37.91)

23 (29.87)

 

HCT-CI

  

0.49

  

 0.17

 0 ~ 1

172 (94.50)

89 (91.75)

 

145 (94.77)

70 (90.91)

 

 2

10 (5.49)

8 (8.25)

 

8 (5.23)

7 (9.09)

 

GVHD prophylaxis

  

0.18

  

0.16

 CSA-based

156 (85.71)

77 (79.38)

 

135 (88.24)

62 (80.52)

 

 FK506-based

26 (14.29)

20 (20.62)

 

18 (11.76)

15 (19.48)

 

 Use of ATG

75(41.21)

97(100)

0.00b

63(41.18)

77(100)

0.00b

Blood type

  

0.80

  

0.78

 Match

75 (41.21)

37 (38.14)

 

63 (41.18)

30 (38.96)

 

 Mismatch

108 (59.34)

59 (60.82)

 

90 (58.82)

47 (61.04)

 

 Neutrophil engraftment

14.62 (15.10)

18.15 (24.17)

0.31

14.96 (16.422)

15.11 (3.272)

0.94

 Platelet engraftment

16.34 (13.19)

17.86 (8.45)

 

16.8 (14.295)

19 (8.785)

0.22

Infection

 Bacteria

69 (37.91)

34 (35.05)

0.70

74 (48.37)

28 (36.36)

0.08

 Fungus

34 (18.68)

30 (30.93)

0.02b

18 (11.76)

7 (10.87)

0.54

 CMV

55 (30.22)

41 (42.27)

0.04b

33 (21.57)

26 (33.77)

0.04b

 aGVHD

64 (35.16)

53 (54.64)

0.00b

52 (33.99)

44 (57.14)

0.00b

 cGVHD

26 (14.29)

11 (11.34)

0.58

26 (16.99)

10 (12.99)

0.43

  1. BMI body mass index, AML acute myelogenous leukemia, ALL acute lymphocyte leukemia, MDS/MPN myelodysplastic syndrome/Myeloproliferative Neoplasm, AA aplastic anemia, CR complete remission, ECOG eastern cooperative oncology Group, HCT-CI hematopoietic cell transplant-comorbidity Index (HCT-CI) score, HSCT hematopoietic stem cell transplantation, MSD matched sibling donor, HID haplo-identical donor, PB peripheral blood, BM bone marrow, CMV cytomegalovirus, aGVHD acute Graft versus Host Disease, cGVHD: chronic graft versus host disease, CSA cyclosporine, FK506 tacrolimus
  2. aValues were expressed as n (%) or median (interquartile range)
  3. bIndicates the statistical significance for the factors